21 results about "Symptomatic treatment" patented technology

The application relates to application of semaglutide in preparation of a medicine for treating or delaying ovarian aging, and through a natural aging mouse model, a cell aging model and transcriptome analysis, it is first proved that semaglutide can significantly increase the number of follicles and reduce the level of aging markers, and from a molecular level, it is revealed that the mechanism of realizing multi-target point delay of ovarian aging is that semaglutide realizes multi-target point delay of ovarian aging through regulating an adipocyte cytokine signal pathway, inhibiting excessive cell division and regulating an NF-kappa B signal pathway. As a marketed drug, semaglutide has clear safety, a long half-life and high patient compliance, and has a significant clinical conversion prospect. The application breaks through the limitation that existing hormone replacement therapy and assisted reproductive technology can only treat symptoms or solve the problem of fertility, provides a first drug intervention strategy which can fundamentally delay the process of follicle depletion, and fills the blank in the field of ovarian aging treatment.

The invention discloses a stagnation-removing composition as well as a preparation method and application thereof, on the basis of four-adverse-qi powder consisting of radix bupleuri, immature bitter orange, red peony root and honey-fried licorice root, liver and spleen qi is regulated and smoothened, and the ascending and descending functions of intestinal tracts are recovered; the fructus kochiae, the fructus cnidii, the fried peach kernels, the fried semen armeniacae amarae, the Chinese waxgourd seeds fried with bran, the ligusticum wallichii, the lumbricus and the schizonepeta spike are creatively combined, so that the effects of promoting blood circulation to remove blood stasis, promoting diuresis to dispel wind and relaxing bowel are synergistically achieved. According to the traditional Chinese medicine composition, the difficulty in defecation can be effectively improved, the pathological links of qi stagnation, damp obstruction and blood stasis can be intervened from the pathogenesis, various uncomfortable symptoms related to abdominal fullness, anus falling expansion, vector qi frequency and the like can be remarkably relieved, the conversion from treatment according to noses to treatment for the root is realized, and a solution with more comprehensive effects and more lasting curative effects is provided.

This application relates to the field of medical diagnosis and treatment technology, specifically to a modular AI-powered fully intelligent diagnostic and treatment instrument and robot for both traditional Chinese medicine (TCM) and Western medicine. It includes: a TCM data acquisition module that constructs a four-diagnostic system (inspection, auscultation, inquiry, and palpation) to acquire TCM data; a Western medicine data acquisition module that constructs a four-diagnostic system (inspection, auscultation, inquiry, and palpation) to acquire Western medicine data; an AI-integrated TCM-Western medicine diagnostic module that uses an improved algorithm based on the fusion theorem definition formula method, Hua Luogeng optimization method, and quantum resonance correction to quantify the TCM data through weighted calculations and pulse diagnosis based on the principles of deficiency and excess; and a module that uses core calculation formulas to analyze the Western medicine data and outputs a TCM-Western medicine integrated diagnostic conclusion; and a treatment plan output module that generates an integrated TCM-Western medicine treatment plan based on the diagnostic conclusion. This integrated TCM-Western medicine treatment plan includes a precise TCM formula combining the principal, assistant, and adjuvant herbs, as well as a Western medicine symptomatic treatment plan. This addresses issues such as the ambiguity of the four diagnostic methods, invasive testing, and insufficient synergy between TCM and Western medicine.

The invention provides a drug rehabilitation traditional Chinese medicine composition. The drug rehabilitation traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 9.6 to 14.4 parts of American ginseng, 17.6 to 26.4 parts of astragalus membranaceus, 10.4 to 15.6 parts of bighead atractylodes rhizome, 10.4 to 15.6 parts of poria cocos, 8 to 12.5 parts of liquorice, 9.6 to 14.4 parts of angelica sinensis, 8 to 12.5 parts of rhizoma picrorhizae, 12 to 18 parts of honeysuckle, 8.8 to 13.2 parts of husks of millet, 8 to 12 parts of catechu, 10.4 to 15.6 parts of durac, 10.4 to 15.6 parts of radix rehmanniae, 10.4 to 15.6 parts of gentiana macrophylla, 10.4 to 15.6 parts of fructus alpiniae oxyphyllae and 17.6 to 26.4 parts of corydalis tuber. The invention further provides a preparation method, application and a quality detection method of the traditional Chinese medicine composition. Experiments prove that the traditional Chinese medicine composition is small in toxic and side effects, stable and controllable in curative effect and low in resorption rate, the acting point is that a large number of tonifying medicines are used for rescuing people firstly, and the symptom is treated by using the symptom-treating medicines, so that the body is recovered as soon as possible, and the treatment compliance of a user who eliminates the abstinence symptom is improved.

This invention relates to the field of biomedical technology and provides the application of taquimod in the preparation of drugs for regulating lymphatic inflammatory responses. Through bioinformatics analysis and cell experiments, this invention demonstrates that taquimod can specifically inhibit the abnormally activated S100A9 / RAGE signaling pathway in lymphatic inflammation, significantly reduce the expression of inflammatory factors, and effectively restore the proliferation, migration, and tube formation function of lymphatic endothelial cells. This provides a novel drug treatment approach based on molecular mechanisms for treating diseases related to lymphatic inflammatory responses such as lymphedema. Furthermore, taquimod, as an oral formulation with proven safety in clinical trials, exhibits good patient compliance and is suitable for long-term use. Compared to existing symptomatic treatments, it holds promise for fundamentally interrupting the vicious cycle of inflammation that drives disease progression, and thus has significant clinical application potential.

The present invention provides a composition for preventing or treating neurodegenerative diseases, containing a novel pyridoindole derivative compound as an active ingredient. The present invention departs from a conventional symptomatic treatment that focused on controlling peripheral symptoms of neurodegenerative diseases, particularly various tauopathies caused by Tau protein aggregation, so as to significantly inhibit the interaction between Tau protein and synaptogyrin-3, and thus can achieve the fundamental removal of the cause of neurodegeneration.

The application provides a wearable light therapy device. The device comprises a base band, a plurality of light emitting elements arranged on the base band, and a controller. The controller is configured to determine a target treatment mode for the patient, determine a plurality of adjustment parameters of a first light emitting element group according to the target treatment mode, and control the plurality of light emitting elements to treat the target part of the patient. The target treatment mode is one of a plurality of treatment modes of the light therapy device for treating a target disease. The first light emitting element group is any one of a plurality of light emitting element groups formed by the plurality of light emitting elements, and the plurality of light emitting element groups correspond to a plurality of sub-parts of the target part. The application can select an appropriate target treatment mode according to the patient's symptoms, and achieve symptomatic treatment and improve treatment effect.

The present invention relates to an aqueous liquid composition or a hydroalcoholic liquid which consists of a mixture which consists of or, alternatively, is composed of a combination of Aloe vera gel, hyaluronic acid and honey and optionally, food and / or pharmaceutical grade additives and / or technological excipients. Said composition is intended for use in the preventive and / or therapeutic treatment of symptoms and disorders associated with gastroesophageal reflux and / or laryngopharyngeal reflux (RLF) and the disease caused by it, for use as an adjuvant in the symptomatic treatment of gastroesophageal and / or laryngopharyngeal reflux, or for use in a preventive and / or therapeutic treatment against: (i) lesions of the oral cavity and the pharyngo-laryngopharyngeal tract (ii) mucositis and / or iii) aphthous ulcers and / or aphthous lesions.

The invention discloses a bone infection composite gel coating pre-solution based on an in-situ injection-in-vivo curing technology as well as a preparation method and an application system of the bone infection composite gel coating pre-solution. The preparation method specifically comprises the following steps: 1) preparing a composite gel coating pre-solution by using methylacryloylated hyaluronic acid, catechol group and nitrobenzene group modified hyaluronic acid, EPS hydrolase, active antibacterial agent loaded methylacryloylated hyaluronic acid microspheres and a photoinitiator; 2) forming an application system by the pre-solution, an endoscopic active material conveying conduit, a conduit controller assembly, a mechanical arm assembly and an imaging assembly; and (3) the catheter controller assembly and the mechanical arm assembly control the endoscopic active material conveying catheter to enter the body through the minimally invasive wound, the imaging assembly performs observation and adjustment until the head of the catheter reaches the surface of a bone implantation instrument, the pre-solution is conveyed to the surface of the instrument, and a UV light source is switched for curing to form an antibacterial gel coating. Starting from the time point after in-vivo infection occurs, symptomatic treatment can be carried out on the infection after the orthopedic instrument implantation operation.

The application discloses a Chaiqin Baihu fever-reducing drink and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The application solves the problems that the existing technology mainly adopts symptomatic treatment for treating fever caused by acute upper respiratory tract infection, and the medication is limited due to various factors, and the clinical curative effect is poor. The traditional Chinese medicine composition for preparing the Chaiqin Baihu fever-reducing drink comprises the following traditional Chinese medicine components in parts by mass: 4-8 parts of Radix Bupleuri, 2-4 parts of Radix Scutellariae, 1-3 parts of Notopterygium, 1-3 parts of Radix Puerariae, 8-12 parts of Gypsum Fibrosum, 1-3 parts of Periostracum Cicadae and 1-3 parts of Rhizoma Dioscoreae. The whole prescription combines Ganhan, Kuhang, Xinyin and Xinglei in one pot, and combines cold and warm, clear and transparent, and defense qi, and is suitable for treating the pathogenesis of exogenous fever.

This invention discloses a traditional Chinese medicine composition for treating acute pharyngitis at high altitudes. The composition comprises the following ingredients in parts by weight: 2-20 parts of Pinellia ternata, 2-20 parts of Cinnamomum cassia, 1-6 parts of Asarum heterotropoides, 2-20 parts of Platycodon grandiflorus, 2-20 parts of Fritillaria thunbergii, 2-20 parts of Terminalia chebula, 2-20 parts of Prunus mume, 2-20 parts of Schisandra chinensis, and 2-20 parts of Glycyrrhiza uralensis. This invention addresses the regionally specific core pathogenesis of acute pharyngitis at high altitudes, characterized by "yang deficiency and failure to transform, and fluid retention." The formula follows the principles of monarch-minister-assistant-guide combination, achieving a synergistic effect of warming yang and transforming qi, resolving phlegm and relieving sore throat, and generating fluids and moistening dryness. It is warming without being drying, and combines dispersing and astringing properties, addressing both the symptoms and the root cause. It fundamentally repairs the imbalanced internal environment of the body, completely overcoming the limitations of simple symptomatic treatment.

The invention relates to an antibody drug for preventing and treating sepsis-related encephalopathy and application thereof. Variable region complementary determining regions and full-length amino acid sequences of a heavy chain and a light chain of an antibody are clear. The sepsis-related encephalopathy is high in morbidity and mortality, existing treatment means are limited, and the core pathogenesis of sepsis-related encephalopathy is related to blood-brain barrier injury and neuroinflammation. The A-FABP antibody 6H2 is combined with A-FABP through high affinity, the integrity of a blood brain barrier is protected, neuronal apoptosis is inhibited, symptoms of sepsis-related encephalopathy are remarkably improved, a breakthrough solution from symptomatic treatment to cause treatment is provided for the sepsis-related encephalopathy, and the A-FABP antibody 6H2 has important clinical application value.

This invention discloses a combination of Western and traditional Chinese medicine for treating gastric ulcers. The combination comprises ① gentamicin (80,000 units / vial) and a combination of gentamicin and a remedy called "Weidele". This combination has anti-inflammatory, laxative, and anti-inflammatory effects when taken orally. It is effective in treating inflammation and is safe to use with an extremely low recurrence rate. Improvement is seen within fifteen days, with no obvious toxic side effects. After approximately ten days of symptomatic treatment with the combination of gentamicin (80,000 units / vial) and remedyle, the condition improved, symptoms disappeared, and a follow-up gastroscopy showed improved lesion absorption. Continued anti-inflammatory treatment and a follow-up gastroscopy at three months were then performed.

The present invention relates to a novel chalcone derivative compound and a composition for the prevention or treatment of neurodegenerative diseases, comprising same as an active ingredient. The present invention can fundamentally eliminate the cause of neurotransmission dysfunction by simultaneously inhibiting the activities of two hyperactivated cholinesterases, unlike conventional symptomatic therapies that focus on the control of peripheral symptoms for various neurodegenerative diseases caused by a decrease in acetylcholine concentration, including Alzheimer's disease.

The invention relates to the technical field of traditional Chinese pharmacology, and particularly discloses a traditional Chinese medicine repair ointment for rhinitis and a preparation method. The ointment is prepared from the following raw materials in parts by weight: 5-9 parts of honeysuckle, 3-7 parts of borneol, 2-5 parts of cocklebur fruit, 1-2.5 parts of asarum, 3-7 parts of peppermint oil and 7-12 parts of vaseline. The preparation method comprises the following steps: S1, cleaning, drying and crushing the honeysuckle flower, the fructus xanthii and the herba asari to obtain pretreated raw materials; s2, crushing borneol, and sieving to obtain borneol fine powder; s3, heating and melting vaseline, mixing with peppermint oil and borneol fine powder, decocting, cooling, sealing and fermenting to obtain a fermented oil material; and S4, mixing the pretreated raw materials with the fermented oil material, decocting, cooling and fermenting again. The traditional Chinese medicine repair ointment is used for local repair and symptomatic treatment of acute and chronic rhinitis and allergic rhinitis, and has the advantages of multi-target synergistic effect, mild and lasting effect and high bioavailability.

The present application relates to the technical field of biological detection, and particularly relates to a Bordetella pertussis nucleic acid detection kit. The present application uses ptxP alone or in combination with IS481 to determine Bordetella pertussis, and there is no cross reaction with pathogenic bacteria causing similar symptoms of pertussis. Meanwhile, the kit has the advantages of high sensitivity and strong specificity, and the detection can be completed in only 50 min, and the minimum detection limit can reach 1 CFU / mL. The kit is suitable for disease screening and clinical diagnosis, can greatly shorten the detection time, improve the detection efficiency, and avoid false positive results, and has important significance in disease monitoring, disease screening, clinical diagnosis and symptomatic treatment.

The application discloses a traditional Chinese medicine composition for treating highland oral ulcer, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: Rhizoma Coptidis 1-20 parts, Jiaogulans 5-30 parts, Anemarrhena 5-30 parts, Phellodendron 1-20 parts, Styrax 1-15 parts, Bletilla 5-30 parts, Evodia 5-30 parts and Glycyrrhiza 1-20 parts. The traditional Chinese medicine composition is highly targeted, directly attacks the core pathogenesis, and precisely adapts to the unique pathogenesis of highland oral ulcer, such as 'dry heat and external attack of fire toxin, deficiency of Zongqi', and is matched according to the corresponding therapeutic principle, and the traditional Chinese medicine composition has the functions of clearing toxin, tonifying Zongqi and nourishing body fluid, so that the problem of easy attack and difficult healing of ulcer is solved from the root, and the traditional Chinese medicine composition is superior to symptomatic treatment of western medicine.

The invention relates to a medicine prescription for treating radiodermatitis and application thereof. The medicine comprises the following components in percentage by weight: 0.01%-2% of acetate of a peptide compound, 2%-5% of a first solvent, 0.05%-1.75% of a bacteriostatic agent, 0.5%-3% of a gel matrix, 0.05%-3% of a metal ion complexing agent, a pH regulator for regulating the pH value to 3-7, and a second solvent supplemented to 100%. The prescription of the medicine for treating radiodermatitis is especially suitable for symptomatic treatment of chronic pruritus such as atopic dermatitis, and the local action mechanism of the medicine gives consideration to both curative effect and safety. The medicine can be directly administered to an affected part, so that the uncertainty of in-vivo circulation is reduced; the use by patients is convenient and the compliance is improved.

To provide a cholera toxin production inhibitor and its use for realizing cholera treatment or cholera prevention by a different approach, which is not the conventional symptomatic treatment and antibacterial treatment. 【Solution means】A cholera toxin production inhibitor containing a compound represented by the following formula (1). TIFF2026058903000007.tif47164 (In formula (1), R 1 , R 2 , R 4 , R 5 , R 6 , and R 7 each independently represent a hydrogen atom, a hydroxyl group, or an alkoxy group having an alkyl group with 1 to 4 carbon atoms, and R 3 represents a hydrogen atom, a formyl group, or a carboxyl group. However, the case where all of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are all hydrogen atoms is excluded.)

Ascites and pleural effusion are common complications, and clinical interventions primarily based on symptomatic treatment often result in poor prognoses. Guided by the new theory of "inflammation-cancer" transformation, this invention discloses a traditional Chinese medicine composition for the prevention and treatment of ascites and pleural effusion, along with its preparation methods for internal and external use. The composition comprises the following medicinal materials in parts by weight: Codonopsis pilosula 3-20 parts, Atractylodes macrocephala 3-20 parts, Cinnamomum cassia 3-18 parts, Trichosanthes kirilowii 3-18 parts, Panax notoginseng 3-12 parts, Lobelia chinensis 3-15 parts, Polygonum bistorta 3-15 parts, Euphorbia helioscopia 3-15 parts, and Lepidium apetalum 3-15 parts. This traditional Chinese medicine composition possesses the effects of strengthening the body's resistance, removing blood stasis, detoxifying, eliminating dampness, promoting diuresis, and reducing swelling. It is effective in preventing and treating inflammatory and malignant ascites and pleural effusion, as well as the associated symptoms such as dyspnea, chest pain, cough, loss of appetite, abdominal pain, abdominal distension, fatigue, and night sweats. It can be prepared as a decoction, granules, pills, capsules, or powder. This invention helps promote the absorption and drainage of pleural and peritoneal effusions, reduce inflammation and fight cancer, adjust and restore the physiological functions of internal organs, and improve the quality of life of patients.